V Schulten1, V Tripple1, K Aasbjerg2, V Backer3, G Lund4, P A Würtzen4, A Sette1, B Peters1. 1. La Jolla Institute for Allergy & Immunology, La Jolla, CA, USA. 2. Department of Cardiology and Center for Cardiovascular Research, Aalborg University Hospital, Aalborg, Denmark. 3. Respiratory Research Unit, Department of Lung Medicine, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark. 4. Global Research, ALK, Hoersholm, Denmark.
Abstract
BACKGROUND:Allergen-specific immunotherapy is the only curative treatment for type I allergy. It can be administered subcutaneously (SCIT) or sublingually (SLIT). The clinical efficacy of these two treatment modalities appears to be similar, but potential differences in the immunological mechanisms involved have not been fully explored. OBJECTIVE: To compare changes in the allergen-specific T cell response induced by subcutaneous vs. sublingual administration of allergen-specific immunotherapy (AIT). METHODS:Grass pollen-allergic patients were randomized into groups receiving either SCIT injections or SLIT tablets or neither. PBMCs were tested for Timothy grass (TG)-specific cytokine production by ELISPOT after in vitro expansion with TG-peptide pools. Phenotypic characterization of cytokine-producing cells was performed by FACS. RESULTS: In the SCIT group, decreased IL-5 production was observed starting 10 months after treatment commenced. At 24 months, T cell responses showed IL-5 levels significantly below the before-treatment baseline. No significant reduction of IL-5 was observed in the SLIT or untreated group. However, a significant transient increase in IL-10 production after 10 months of treatment compared to baseline was detected in both treatment groups. FACS analysis revealed that IL-10 production was associated with CD4(+) T cells that also produced IFNγ and therefore may be associated with an IL-10-secreting type 1 cell phenotype. CONCLUSION AND CLINICAL RELEVANCE: The most dominant immunological changes on a cellular level were a decrease in IL-5 in the SCIT group and a significant, transient increase of IL-10 observed after 10 months of treatment in both treated groups. The distinct routes of AIT administration may induce different immunomodulatory mechanisms at the cellular level.
RCT Entities:
BACKGROUND: Allergen-specific immunotherapy is the only curative treatment for type I allergy. It can be administered subcutaneously (SCIT) or sublingually (SLIT). The clinical efficacy of these two treatment modalities appears to be similar, but potential differences in the immunological mechanisms involved have not been fully explored. OBJECTIVE: To compare changes in the allergen-specific T cell response induced by subcutaneous vs. sublingual administration of allergen-specific immunotherapy (AIT). METHODS: Grass pollen-allergicpatients were randomized into groups receiving either SCIT injections or SLIT tablets or neither. PBMCs were tested for Timothy grass (TG)-specific cytokine production by ELISPOT after in vitro expansion with TG-peptide pools. Phenotypic characterization of cytokine-producing cells was performed by FACS. RESULTS: In the SCIT group, decreased IL-5 production was observed starting 10 months after treatment commenced. At 24 months, T cell responses showed IL-5 levels significantly below the before-treatment baseline. No significant reduction of IL-5 was observed in the SLIT or untreated group. However, a significant transient increase in IL-10 production after 10 months of treatment compared to baseline was detected in both treatment groups. FACS analysis revealed that IL-10 production was associated with CD4(+) T cells that also produced IFNγ and therefore may be associated with an IL-10-secreting type 1 cell phenotype. CONCLUSION AND CLINICAL RELEVANCE: The most dominant immunological changes on a cellular level were a decrease in IL-5 in the SCIT group and a significant, transient increase of IL-10 observed after 10 months of treatment in both treated groups. The distinct routes of AIT administration may induce different immunomodulatory mechanisms at the cellular level.
Authors: S Benjaponpitak; A Oro; P Maguire; V Marinkovich; R H DeKruyff; D T Umetsu Journal: J Allergy Clin Immunol Date: 1999-03 Impact factor: 10.793
Authors: Christian Möbs; Henrik Ipsen; Lea Mayer; Caroline Slotosch; Arnd Petersen; Peter A Würtzen; Michael Hertl; Wolfgang Pfützner Journal: J Allergy Clin Immunol Date: 2012-09-27 Impact factor: 10.793
Authors: K Aasbjerg; V Backer; G Lund; J Holm; N C Nielsen; M Holse; V R Wagtmann; P A Würtzen Journal: Clin Exp Allergy Date: 2014-03 Impact factor: 5.018
Authors: Michael Blaiss; Jennifer Maloney; Hendrik Nolte; Sandra Gawchik; Ruji Yao; David P Skoner Journal: J Allergy Clin Immunol Date: 2011-01 Impact factor: 10.793
Authors: Carla Oseroff; John Sidney; Maya F Kotturi; Ravi Kolla; Rafeul Alam; David H Broide; Stephen I Wasserman; Daniela Weiskopf; Denise M McKinney; Jo L Chung; Arnd Petersen; Howard Grey; Bjoern Peters; Alessandro Sette Journal: J Immunol Date: 2010-06-16 Impact factor: 5.422
Authors: Erik Wambre; Jonathan H DeLong; Eddie A James; Nadia Torres-Chinn; Wolfgang Pfützner; Christian Möbs; Stephen R Durham; Stephen J Till; David Robinson; William W Kwok Journal: J Allergy Clin Immunol Date: 2013-12-25 Impact factor: 10.793
Authors: J Pham; C Oseroff; D Hinz; J Sidney; S Paul; J Greenbaum; R Vita; E Phillips; S Mallal; B Peters; A Sette Journal: Clin Exp Allergy Date: 2016-07-26 Impact factor: 5.018
Authors: Carla Oseroff; John Pham; April Frazier; Denise Hinz; John Sidney; Sinu Paul; Jason A Greenbaum; Randi Vita; Bjoern Peters; Véronique Schulten; Alessandro Sette Journal: Ann Allergy Asthma Immunol Date: 2016-12 Impact factor: 6.347
Authors: Amedee Renand; Mohamed H Shamji; Kristina M Harris; Tielin Qin; Erik Wambre; Guy W Scadding; Peter A Wurtzen; Stephen J Till; Alkis Togias; Gerald T Nepom; William W Kwok; Stephen R Durham Journal: J Allergy Clin Immunol Date: 2017-11-09 Impact factor: 10.793